OGEN — ORAGENICS INC
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1174940 ·
Last close
$0.50
Market Cap
$2.26M
52W High
$0.66
52W Low
$0.48
ADV30
31,823
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,255,927 | -2,201,243 | 7,489,636 | 6,107,078 | 1,307,878 |
| Dec 2025 | 0 | — | -2,498,301 | -2,286,870 | 10,067,764 | 4,399,726 | 1,786,359 |
| Sep 2025 | 0 | — | -3,123,773 | -3,066,589 | 12,705,544 | 11,403,766 | 2,874,108 |
| Jun 2025 | 0 | — | -1,714,202 | -2,272,035 | 2,139,708 | 1,973,745 | 4,267,423 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,246,387
Investing CF
$0
Financing CF
$16,781,273
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-19.98
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-226,628,659
Inventory
—
Receivables
$53,082
ST Investments
$4,000,000
EBIT TTM
$-9,193,467
Pretax Income TTM
$-9,979,397
Interest Exp TTM
$785,930
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,362,503 | -9,842,487 | 10,067,764 | 1,786,359 | — | -9,246,387 |
| Dec 2024 | 0 | -10,558,815 | -10,567,918 | 1,472,510 | 1,684,395 | — | -8,597,382 |
| Dec 2023 | 0 | -20,904,903 | -20,655,737 | 4,966,335 | 1,798,181 | — | -7,290,880 |
| Dec 2022 | 0 | -14,420,768 | -14,288,389 | 14,758,025 | 1,748,723 | — | -15,228,483 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-10.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VCNX | VACCINEX, INC. | $2.28M | $0.85 | — |
| PCYN | PROCYON CORP | $2.28M | $0.28 | — |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $2.22M | $3.80 | — |
| PPCB | Propanc Biopharma, Inc. | $2.30M | $1.01 | — |
| DCOY | Decoy Therapeutics Inc. | $2.19M | $4.11 | — |
News headlines (Yahoo Finance, 1h cache)
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
2026-07-07 12:30 · Yahoo
Sidoti Events, LLC's May Micro-Cap Virtual Conference
2026-05-20 11:30 · Yahoo
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
2026-05-19 12:45 · Yahoo
ORAGENICS PROVIDES INVESTOR UPDATE
2026-05-18 12:30 · Yahoo
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
2026-05-07 12:30 · Yahoo
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
2026-05-05 12:30 · Yahoo
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
2026-04-20 13:00 · Yahoo
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
2026-04-13 12:30 · Yahoo
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
2026-03-25 22:30 · Yahoo
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
2026-03-17 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.